Integrating risk minimization planning throughout the clinical development and commercialization lifecycle: an opinion on how drug development could be improved
Elaine H Morrato,1 Meredith Y Smith2 1Colorado School of Public Health, University of Colorado, Anschutz Medical Campus, Aurora, CO, 2EMD Serono, Inc, Rockland, MA, USA Abstract: Pharmaceutical risk minimization programs are now an established requirement in the regulatory landscape. However, pharma...
Enregistré dans:
| Auteurs principaux: | , |
|---|---|
| Format: | Livre |
| Publié: |
Dove Medical Press,
2015-02-01T00:00:00Z.
|
| Sujets: | |
| Accès en ligne: | Connect to this object online. |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Internet
Connect to this object online.3rd Floor Main Library
| Cote: |
A1234.567 |
|---|---|
| Exemplaire 1 | Disponible |